The 2022 lymphoid neoplasm classification updates from the World Health Organization and the International Consensus Classification Clinical Advisory Committee agree in defining chronic lymphocytic leukemia (CLL) as a low-grade lymphoproliferative neoplasm with ≥5 × 109/L clonal B-cells in the peripheral circulation that express CD5, CD19, CD20(dim), and CD23 [1, 2]. The gene discussed is FCER2; the disease is B-cell chronic lymphocytic leukemia.